Dopaminergic imaging in patients with basal ganglia calcification presenting with parkinsonism
Objective: To evaluate the integrity of the nigro-striatal system with single photon emission computed tomography imaging with dopamine transporter (DaTscan) in patients with basal ganglia…Analysis of secondary causes in Fahr’s syndrome and whole exome sequencing in Fahr disease from Northeast China and South Korean
Objective: In this study, patients with Fahr syndrome were analyzed for etiology, and genetic testing was performed for patients with Fahr disease from Northeast China…Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS
Objective: Neuroinflammation is a pathological hallmark of several neurodegenerative diseases. We speculated that reduction of calcium ion influx specifically in neurons should reduce inflammatory cellular…Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor
Objective: To investigate the effects of selective phosphodiestrase (PDE) inhibitors in Nimodipine induced neuro degeneration (animal models of Huntington’s disease) in rats. Background: Nimodipine is…Bone health and laboratorial correlations of Vitamin D in Parkinson’s disease
Objective: To evaluate the correlation between levels of 25 (OH)D (Vitamin D) and Bone Mineral Density (BMD) in a parkinsonian population. Background: Considering a limiting…Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia
Objective: To identify patterns of striatal projection neurons (SPN) activities that code for akinetic and dyskinetic movement disorders in a mouse model of hemiparkinsonism and…Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models
Objective: In this study, we utilized preclinical data to establish predicted human therapeutic exposures of the potent, selective and state-dependent Cav3 channel antagonist, CX-8998, currently…A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale
Objective: The objective of this study is to access the efficacy of CX-8998 using the MDS-UPDRS Tremor Score (MDS-UPDRS-TS) and a digital biomarker platform, while…Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor
Objective: To study the pharmacodynamics (PD) of CX-8998, using pharmaco-electroencephalography (phEEG) and define plasma concentrations of CX-8998 which are pharmacologically active on objective CNS parameters.…Genetic and Clinical Analysis of Cerebral Calcifications
Objective: Genetic and clinical analysis in primary cerebral calcification. Background: Cerebral calcification is associated with a variety of disorders of different aetiologies. To date, the primary…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.